Requirements for labelling of medicinal products are according to Regulation The Nordic Medicines Agencies have prepared guidance documents to facilitate the manufacturing of Nordic packages for both human and veterinary medicinal products.

This present, revised, version of the Guidelines on Good Labelling Practice for Pesticides targets pesticide regulatory authorities, primarily in developing countries and countries with economies in transition, which have to define or revise national pesticide labelling requirements. If you would like to know more, please sign-up for our on-demand webinars covering EMA, Health Canada and FDA regulations. On October 9, 2017, the European Medicines Agency (EMA) announced that the annex to the guideline on excipients in labeling and packaging of drug products has been updated to include all excipients that must be listed in the labeling and packaging leaflets of drugs and their safety warnings.. By using our services, you agree that we use cookies. For all other medicinal products, only excipients that are known to have a recognised action or effect included in this guideline, should be stated on the labelling. Packaging ‘blue-box’ requirements and additional information on labelling/package leaflet for products authorised via national, mutual recognition, decentralised or centralised procedures . In cases in which you can order through the Internet we have established a hyperlink. Nordic packages. A mock-up for the intended packaging to be used while the product is not available in approved packaging.

European Commission guideline on “Excipients in the labelling and patient information leaflet of medicinal products for human use” (or EMA website) • EudraLex - Volume 2 - Pharmaceutical legislation on no tice to applicants and regulatory guidelines for medicinal products for human use: “Guideline on the readability of the Guidelines Detail; The following guideline can be ordered through the address listed in the "Source/Publisher"-category. Version 22/12/2014 . Requirements for labelling of medicinal products are according to Regulation No.545/2018 (in Icelandic only) on marketing authorisations for proprietary medicinal products, their labelling and PILs. Short Title: Annex 13.

Requirements for labelling on packaging. This is a compilation of our recent and real-time experience. • The Agency is committed to actively engage with national competent ... 201310108_Prizzi_M_EMA review process of medicines labelling and packaging_rev 08.10.13

Labeling should comply with the requirements of Directive 2003/94/EC.

EMA/CMDv/391895/2012 . Furthermore, exemptions can be granted for the PIL being in Icelandic if the product is not given directly to the patient for self-medication or owner/possessor of an animal in the case of a veterinary medicinal product. use of a centralised randomization system: In cases in which you can order through the Internet we have established a hyperlink.European Commission, Enterprise and Industry; http://ec.europa.eu/enterprise/If you have problems displaying the website, is maybe JavaScript disabled on your browser, or your browser does not support JavaScript!Cookies help us in providing our services. IMA can also grant an exemption from generally required information on the labelling or the PIL. )In exceptional cases IMA can grant provisional exemptions from approved packaging in order to alleviate shortage of specific medicinal products. EudraLex Vol 4, Annex 13: Investigational Medicinal Products

:In the case of medicinal products indicated for rare diseases, IMA can permit labelling and PILs to be in English or in a Nordic language other than Finnish.

(Source Directive 2001/83/EC art.63 (human medicinal products) and Directive 2001/82/EC, art.61 (veterinary medicinal products). If the packaging does not have the same product ID (Nordic Number) as an approved packaging, the MAH must confirm the equivalence of the products.

The following information should be included on labels, unless its absence can be justified, e.g. Additional information on labelling… • Despite the challenges, we are making significant progress in this area.